ConV2X Smart Tech Transformation in Healthcare & Life Sciences 2026

We have misdiagnosed the problem in American healthcare. Rising costs, poor outcomes, and system fragility are not the disease — they are symptoms. This keynote reframes the debate: where the real failures lie, what the data actually shows, and what genuine reform requires. A provocative, evidence-based call to action.

AI. Public health. Policy. Economics. Investment. A rapid, high-level examination of the developments changing healthcare and life sciences, what mattered over the past 12 months, and the signals likely to matter most in 2027.

AI is moving from administrative assistance into clinical decision-making, diagnostics, and patient-facing care. Where does software become a medical device? What evidence should be required before deployment? How should leaders interpret approval, explainability, bias, model risk, and clinical responsibility? And when an AI-supported decision causes harm, who is accountable?

The question is no longer whether virtual care, remote monitoring, and digital health can be deployed. It is where they measurably improve care. Leaders examine clinical outcomes, adoption, workflow integration, patient engagement, equity, and the evidence required to move from promising technology to sustainable models of care.

What did we actually fix after COVID — and what remains unresolved? From emerging infectious disease and zoonotic threats to digital surveillance and AI-enabled detection, leaders examine whether public-health, hospital, and technology infrastructure can identify and respond to the next threat before it becomes the next crisis.

AI and advanced data systems are moving upstream into clinical development, trial design, patient identification, evidence generation, and the relationship between life sciences and care delivery. Where are they creating measurable value? How should new forms of evidence be validated? And what changes when increasingly intelligent systems become part of the scientific and clinical-development process?

Healthcare has no shortage of innovation. The harder question is whether incentives, reimbursement, cost, access, and investment are aligned with better outcomes. Leaders examine where technology is creating measurable value, where payment and business models break down, what decision-makers should demand before scaling, and what is simply adding cost.

Accuracy is not the same as clinical value. What evidence should clinicians, researchers, and health systems demand before AI enters real-world care? This discussion examines validation, patient safety, workflow fit, bias, generalizability, real-world evidence, and the difference between an impressive model and a system that actually improves outcomes.

Selected innovators present technologies addressing consequential healthcare and life-sciences problems. Investor and audience discussion followed by networking and reception. Direct access to potential partners, investors, and decision-makers — creating connections that can lead to funding, pilots, and commercial collaboration.

Where is capital chasing hype? Which healthcare and life-sciences problems are actually worth solving? What evidence should investors demand? Investors, founders, clinicians, and healthcare leaders examine what can create durable value — and what the market should stop funding.

Eight minutes per table in a rotating format: six-minute pitch and two-minute Q&A. Investors score confidentially.

Investors share candid observations. Selected startups are recognized and founders and investors continue conversations informally.

Technology alone doesn’t transform healthcare. Decisions about evidence, people, incentives, governance, infrastructure, and implementation do. What separates organizations that accumulate technologies from those that actually improve outcomes — and what must leaders put in place now?

Health AI is crossing borders faster than governance is converging. Different jurisdictions are taking different approaches to safety, accountability, data sovereignty, and algorithmic risk while access remains profoundly uneven. Can global principles coexist with national regulation? Who sets the rules — and who risks being left behind?

AI, connected devices, cloud infrastructure, health data, and increasingly autonomous systems are expanding healthcare’s attack surface. What vulnerabilities are organizations creating faster than they can govern them? How should security be built into architecture rather than added after deployment? And which threats are leaders underestimating?

Virtual care, remote monitoring, connected devices, and digital platforms are extending care beyond hospital walls. What infrastructure makes that clinically useful, interoperable, secure, equitable, and financially sustainable? Leaders examine the connection between hospitals, homes, specialists, patients, devices, and data — and where real-world care still breaks.

Healthcare is moving from AI that answers questions to AI that takes action. What happens when agents coordinate care, initiate workflows, monitor conditions, or act across clinical and enterprise systems? Where must human authority remain? What happens when autonomous systems interact? And when something goes wrong, who owns the decision?

Agentic systems. Robotics. Digital twins. Ambient intelligence. Advanced diagnostics. Edge AI. Synthetic data. Privacy-enhancing technologies. Which emerging technologies could materially change healthcare, research, and life sciences — and which are being overhyped?

A candid assessment of health innovation against the measures that ultimately matter: evidence, outcomes, economics, adoption, scalability, and risk. What’s delivering? What’s failing? What needs fixing? And what are organizations continuing to fund despite weak evidence or limited value?

What are we overestimating? What are we underestimating? What should healthcare and life sciences stop doing? Where should capital and leadership attention move now? And which decisions cannot wait another five years? Leaders from across disciplines identify the choices most likely to shape health and medicine through 2030.

Summit takeaways  ·  Venture2X recognition  ·  Closing